Pharma Equity Group A/S Cl A
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022… Read more
Pharma Equity Group A/S Cl A (PEG) - Total Assets
Latest total assets as of June 2025: Dkr62.30 Million DKK
Based on the latest financial reports, Pharma Equity Group A/S Cl A (PEG) holds total assets worth Dkr62.30 Million DKK as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharma Equity Group A/S Cl A - Total Assets Trend (2008–2024)
This chart illustrates how Pharma Equity Group A/S Cl A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pharma Equity Group A/S Cl A - Asset Composition Analysis
Current Asset Composition (September 2024)
Pharma Equity Group A/S Cl A's total assets of Dkr62.30 Million consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 2.4% |
| Accounts Receivable | Dkr60.29 Million | 91.9% |
| Inventory | Dkr0.00 | 0.0% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr0.00 | 0.0% |
| Goodwill | Dkr0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Pharma Equity Group A/S Cl A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharma Equity Group A/S Cl A's current assets represent 99.6% of total assets in 2024, an increase from 81.4% in 2008.
- Cash Position: Cash and equivalents constituted 2.4% of total assets in 2024, down from 3.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 91.9% of total assets.
Pharma Equity Group A/S Cl A Competitors by Total Assets
Key competitors of Pharma Equity Group A/S Cl A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Pharma Equity Group A/S Cl A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Pharma Equity Group A/S Cl A generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Pharma Equity Group A/S Cl A is currently not profitable relative to its asset base.
Pharma Equity Group A/S Cl A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.02 | 1.92 | 10.15 |
| Quick Ratio | 8.02 | 1.92 | 10.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr53.97 Million | Dkr 29.65 Million | Dkr 65.24 Million |
Pharma Equity Group A/S Cl A - Advanced Valuation Insights
This section examines the relationship between Pharma Equity Group A/S Cl A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.05 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -3.1% |
| Total Assets | Dkr65.61 Million |
| Market Capitalization | $13.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pharma Equity Group A/S Cl A's assets below their book value (0.21 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Pharma Equity Group A/S Cl A's assets decreased by 3.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Pharma Equity Group A/S Cl A (2008–2024)
The table below shows the annual total assets of Pharma Equity Group A/S Cl A from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | Dkr65.61 Million | -3.15% |
| 2023-09-30 | Dkr67.74 Million | -4.69% |
| 2022-09-30 | Dkr71.07 Million | +11.67% |
| 2021-09-30 | Dkr63.65 Million | +10.53% |
| 2020-09-30 | Dkr57.58 Million | -28.77% |
| 2019-09-30 | Dkr80.84 Million | 0.00% |
| 2018-09-30 | Dkr80.84 Million | -6.33% |
| 2017-09-30 | Dkr86.30 Million | -31.37% |
| 2016-09-30 | Dkr125.75 Million | -0.40% |
| 2015-09-30 | Dkr126.25 Million | +1.84% |
| 2014-09-30 | Dkr123.97 Million | -50.66% |
| 2013-09-30 | Dkr251.24 Million | -50.14% |
| 2012-09-30 | Dkr503.85 Million | -0.77% |
| 2011-09-30 | Dkr507.76 Million | +2.11% |
| 2010-09-30 | Dkr497.26 Million | +556.84% |
| 2009-09-30 | Dkr75.70 Million | -71.07% |
| 2008-09-30 | Dkr261.67 Million | -- |